Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Next Previous
Trial Profile

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cendakimab (Primary) ; Cendakimab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HEROES
  • Sponsors Celgene Corporation; Receptos

    • Most Recent Events

    • 25 Feb 2019 Results of an exploratory substudy assessing the effect of RPC4046 on Epithelial-Mesenchymal Transition in adults with active eosinophilic esophagitis, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 25 Feb 2019 Results from open-label extension phase of this study presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 25 Feb 2019 Results of a post-hoc analysis assessing RPC4046 in steroid-refractory subjects, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top